ABSTRACT
Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison of these adverse effects to the common cutaneous manifestations of COVID-19 is provided. Numerous drug-to-drug interactions exist between nirmatrelvir-ritonivir and commonly-used medications within dermatology.
Subject(s)
COVID-19 , Drug-Related Side Effects and Adverse Reactions , Humans , Ritonavir , LactamsSubject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Injection Site Reaction/diagnosis , Skin Diseases/diagnosis , Vaccines, Synthetic/adverse effects , COVID-19 Vaccines/genetics , Dermatologists , Female , Health Knowledge, Attitudes, Practice , Humans , Injection Site Reaction/etiology , Injection Site Reaction/therapy , Male , Patient Education as Topic , Physician's Role , Randomized Controlled Trials as Topic , Skin Diseases/etiology , Skin Diseases/therapy , Spike Glycoprotein, Coronavirus/genetics , Vaccines, Synthetic/geneticsABSTRACT
Owing to the COVID-19 outbreak, the use of telemedicine applications has increased throughout the United States. Using an algorithm to analyze mobile application rankings, we were able to examine how applications with telemedicine services have increased in prevalence and rank pre- and post- COVID-19. Telemedicine apps saw an increase of 210.92 ranked positions on average. Within US telehealth, skin conditions have become the fifth most common diagnosis. Widespread use of teledermatology has been well-accepted. Dermatologists and patients report high satisfaction using teledermatology during COVID-19 and intend to continue using these services in the future. COVID-19 has assisted in reducing physician concerns previously preventing some dermatologists from utilizing teledermatology in their services. Additionally, the geographical and socioeconomic barriers preventing some patients from receiving dermatologic care have been minimized through the use of teledermatology. Addressing these obstacles for dermatologic care improves healthcare equity.